DON WHITLEY SCIENTIFIC – THE LEADING INTERNATIONAL SUPPLIER TO THE MICROBIOLOGY AND TISSUE CULTURE INDUSTRIES


Contact Us +44 (0) 1274 595728 sales@dwscientific.co.uk

Follow Don Whitley Scientific

Archive for February, 2017

KONICA MINOLTA DIGITAL CAMERA

Molecular Targeting of Hypoxia in Radiotherapy

Most solid tumours exhibit areas of both chronic and acute hypoxia, all of them evolving dynamically as a function of cellular growth, vascularisation, oxygen consuming metabolism and therapy response. Tumour hypoxia, generally far below 1% oxygen, correlates with increased recurrence rates and decreased survival rates in most cancers, so the recent review by Hypoxystation users Rey et al. describing “Molecular Targeting of Hypoxia in Radiotherapy” gives a valuable overview of the mechanisms cancer cells have developed to respond to hypoxia.

Dr. Rey of the Princess Margaret Cancer Centre in Toronto, Canada, and his co-authors Luana Schito, Marianne Koritzinsky and Brad Wouters have contributed vastly to our knowledge about the cellular response to hypoxia in the context of tumour behavior. Since 2009, they have acquired four Hypoxystations for their lab, in order to culture cells under conditions which authentically mimic the physiological environment of cancer. The Hypoxystation provides a closed workstation format for rigorous control of oxygen, CO2, temperature and humidity, facilitating accurate regulation of cell culture conditions as the in vivo tumour situation is simulated.

 

Clipboard01

 

In their 2016 review, Rey et al. describe the cellular response to the complex interplay of temporal and spatial variations in oxygen levels, and the rippling effects exerted on vascular, stromal and immunological responses.

 

Brad Wouters quote

By Burga Kalz Fuller, HypOxygen

H45_HEPA_1000x1000

Hypoxia and Tumor Metabolism in Whistler

Information on an upcoming exhibition in Whistler for HypOxygen. Words by Dr Burga Kalz Fuller.

At 2140 feet in Whistler, BC, the air will be getting thinner at the Keystone Symposia on “Adaptations to Hypoxia in Physiology and Disease” joint with the meeting on “Tumour Metabolism: Mechanisms and Targets”. But after all, hypoxia is what we do at HypOxygen, so we are very excited to be spending time at altitude with old friends and new ones on March 5-9.

At the Keystone Symposia in Whistler, HypOxygen will be exhibiting Whitley Hypoxystations for low oxygen cell culture under in vivo conditions. Conceived as an incubator workstation, but allowing gloveless access “to avoid spikes of normoxia” for cancer cells accustomed to very low oxygen, the Hypoxystation enables researchers to culture and manipulate cells growing at consistent oxygen, CO2, humidity and temperature. Another member of the Hypoxystation family, the i2 Instrument Workstation, was developed specifically to house instrumentation such as the Agilent Seahorse XF Analyzer for metabolism assays at hypoxia.

Since seeing is believing, we are greatly looking forward to talks and posters by a number of researchers who use Hypoxystations for their hypoxic cell culture. The broad range of these researchers’ presentations clearly illustrates how closely oxygen availability is linked to cancer cell behavior and metabolism, as the Hallmarks of Cancer are influenced and even determined by hypoxia in the tumour environment. These Hypoxystation users will be presenting data in Whistler:

  • Nicholas Denko, Ohio State University, USA
    Hypoxic Regulation of Mitochondrial Function
  • Almut Schulze, University of Würzburg/Theodor-Boveri Institute, Germany
    Targeting Glucose and Lipid Metabolism in Cancer
  • Janine T. Erler, University of Copenhagen, Denmark
    Hypoxia-Driven ECM Remodelling during Cancer Progression
  • Navdeep S. Chandel, Northwestern University, USA
    Why Mammalian Cells Respire?
  • Sara M. Timpano, University of Guelph, Canada
    Human Cells Cultured Under Physiological Oxygen Utilize a Different Mode of Translation Initiation, Have Higher Proliferation Rates, Less Oxidized DNA and More Tubular Mitochondria
  • Karen H. Vousden, Beatson Institute for Cancer Research, UK
    A Role for p53 in the Adaptation to Metabolic Stress
  • Cormac Taylor, University College Dublin, Ireland
    The Role of Hypoxia in Immunity and Inflammation
  • Eyal Gottlieb, Technion Integrated Cancer Center, Israel
    Metabolic Dependencies of Leukemic Stem Cells
  • Bradly G. Wouters, University Health Network, Canada
    ULK1 Regulates Oxygen Metabolism, Hypoxia Tolerance and Is a Therapeutic Target in Pancreatic Cancer
  • Ester M. Hammond, University of Oxford, UK
    Ribonucleotide Reductase Favors the RRM2B Subunit to Maintain DNA Replication in Hypoxia

 

Please stop by our exhibit at the Whistler Conference Center to learn more about the ways the Hypoxystation can recreate the tumour environment for your cancer research. We also have a “heart-warming” gift for you!

 

Hallmarks of Cancer

capture

Hypoxia and the Hallmarks of Cancer

Therapeutic Targeting of Hypoxia and HIFs in Cancer. Dr Burga Kalz Fuller from US distributor HypOxygen has summarised this study that outlines the Hallmarks of Cancer.

“Tumour hypoxia and HIFs affect most of the cancer hallmarks… and contribute to chemo- and radiotherapy resistance.” In their review from 2016, Wigerup, Pahlman and Bexell of Lund University in Sweden discuss how hypoxia inducible factors HIFs regulate the hypoxic microenvironment in cancer, and the therapeutic strategies that are being developed to improve patients’ prognosis. Dr. Sven Pahlman’s lab has been using the H35 Hypoxystation for more than 5 years, to research SCLC and neuroblastoma, and their data is contributing to the understanding of the role of oxygen levels in the progression of cancer.

Hypoxia and HIF-1α and 2α expression in cancer usually signify a worse prognosis, but most hypoxia-induced transcriptional, translational, and epigenetic changes are cell-type specific. Many effects engendered by hypoxia are mediated directly or indirectly via HIF pathways, and most are causative of the iconic “Hallmarks of Cancer” that Hanahan and Weinberg introduced in 2000 and expanded in 2011. Hypoxia induces increased autophagy, apoptosis, and aberrant cell proliferation; neoangiogenesis mediated by VEGF and PDGF-β; proliferation of cancer stem cells; metabolic reprogramming to satisfy energy and synthetic requirements in proliferating cells; modulation of inflammation and immune responses; genomic instability through increased mutagenesis and diminished DNA repair; and metastasis as hypoxia induces epithelial-to-mesenchymal transition and degradation of the extracellular matrix. Assaying the relationship between hypoxia and the Hallmarks of Cancer benefits significantly from the physiological atmosphere mimicked in the Hypoxystation, a closed-culture hypoxia workstation controlling gasses, temperature and humidity.


Visit Don Whitley Scientific and HypOxygen at

Keystone Adaptations to Hypoxia and Tumour Metabolism

Location: Whistler, BC  Date: 5th – 9th March

Sven Pahlman


In their review, Wigerup and Pahlman describe the role tumour hypoxia plays for cancer therapy and treatment resistance, as oxygen levels, production of reactive oxygen species ROS, and HIF activity are intertwined actors in the cancer battle. Any and all effects of hypoxia are cell-type specific; however, numerous studies indicate that HIF’s mediate chemoresistance, suggesting that HIF-1 and 2 inhibitors can effectively support cancer therapy. The authors state that “since hypoxia is a hallmark of solid tumours and mediates aggressive, metastatic, and resistant disease, it is arguably one of the most attractive therapeutic targets in cancer.” Strategies selectively targeting hypoxia for cancer therapy include hypoxia-activated prodrugs; inhibitors of HIF mRNA and protein expression; and inhibitors of downstream HIF signalling pathways such as VEGF. Effective drug research relies on authentic replication of the hypoxic environment for cell culture: the Hypoxystation used in the Pahlman lab is able to accommodate long-term assays with sterile steam humidification and HEPA clean air. The Hypoxystation concept “Choose your Atmosphere – Define your Environment” is the best way to ensure cell culture reflects physiology in cancer research and therapy.

Hypoxia is at the heart of the Hallmarks of Cancer, and results such as these from the Pahlman lab make the cancer research community hopeful that “HIF inhibition is likely to be a powerful therapeutic approach” to eradicate cancer.

Hallmarks of Cancer

capture

Hypoxia and the Hallmarks of Cancer

Therapeutic Targeting of Hypoxia and HIFs in Cancer. Dr Burga Kalz Fuller from US distributor HypOxygen has summarised this study that outlines the Hallmarks of Cancer.

“Tumour hypoxia and HIFs affect most of the cancer hallmarks… and contribute to chemo- and radiotherapy resistance.” In their review from 2016, Wigerup, Pahlman and Bexell of Lund University in Sweden discuss how hypoxia inducible factors HIFs regulate the hypoxic microenvironment in cancer, and the therapeutic strategies that are being developed to improve patients’ prognosis. Dr. Sven Pahlman’s lab has been using the H35 Hypoxystation for more than 5 years, to research SCLC and neuroblastoma, and their data is contributing to the understanding of the role of oxygen levels in the progression of cancer.

Hypoxia and HIF-1α and 2α expression in cancer usually signify a worse prognosis, but most hypoxia-induced transcriptional, translational, and epigenetic changes are cell-type specific. Many effects engendered by hypoxia are mediated directly or indirectly via HIF pathways, and most are causative of the iconic “Hallmarks of Cancer” that Hanahan and Weinberg introduced in 2000 and expanded in 2011. Hypoxia induces increased autophagy, apoptosis, and aberrant cell proliferation; neoangiogenesis mediated by VEGF and PDGF-β; proliferation of cancer stem cells; metabolic reprogramming to satisfy energy and synthetic requirements in proliferating cells; modulation of inflammation and immune responses; genomic instability through increased mutagenesis and diminished DNA repair; and metastasis as hypoxia induces epithelial-to-mesenchymal transition and degradation of the extracellular matrix. Assaying the relationship between hypoxia and the Hallmarks of Cancer benefits significantly from the physiological atmosphere mimicked in the Hypoxystation, a closed-culture hypoxia workstation controlling gasses, temperature and humidity.


Visit Don Whitley Scientific and HypOxygen at

Keystone Adaptations to Hypoxia and Tumour Metabolism

Location: Whistler, BC  Date: 5th – 9th March

Sven Pahlman


In their review, Wigerup and Pahlman describe the role tumour hypoxia plays for cancer therapy and treatment resistance, as oxygen levels, production of reactive oxygen species ROS, and HIF activity are intertwined actors in the cancer battle. Any and all effects of hypoxia are cell-type specific; however, numerous studies indicate that HIF’s mediate chemoresistance, suggesting that HIF-1 and 2 inhibitors can effectively support cancer therapy. The authors state that “since hypoxia is a hallmark of solid tumours and mediates aggressive, metastatic, and resistant disease, it is arguably one of the most attractive therapeutic targets in cancer.” Strategies selectively targeting hypoxia for cancer therapy include hypoxia-activated prodrugs; inhibitors of HIF mRNA and protein expression; and inhibitors of downstream HIF signalling pathways such as VEGF. Effective drug research relies on authentic replication of the hypoxic environment for cell culture: the Hypoxystation used in the Pahlman lab is able to accommodate long-term assays with sterile steam humidification and HEPA clean air. The Hypoxystation concept “Choose your Atmosphere – Define your Environment” is the best way to ensure cell culture reflects physiology in cancer research and therapy.

Hypoxia is at the heart of the Hallmarks of Cancer, and results such as these from the Pahlman lab make the cancer research community hopeful that “HIF inhibition is likely to be a powerful therapeutic approach” to eradicate cancer.

 

Hallmarks of Cancer

dws logo

MEDLAB 2017

Export representatives from Don Whitley Scientific have been at MEDLAB 2017, an international conference in Dubai that is one of the biggest exhibitions for the Middle East healthcare industry. Formerly the event was a joint venture with Arab Health, but MEDLAB is now its own independent event. Don Whitley Scientific had exhibition stand at the event which displayed a Whitley A35 Anaerobic Workstation and the Whitley Jar Gassing System.

MEDLAB houses 700 exhibitors from 38 countries, giving delegates access to cutting edge products and services from all continents. As well as this huge exhibition, the event also features an extensive lecture programme including topics such as Haematology, Clinical Microbiology and Immunology. The event was held at the Dubai International Convention and Exhibition Centre. As well as offering delegates access to new and developing products from a diverse range of companies, the event was also an opportunity for those wanting to make business connections and expand their distributor network.

 

Medlab 2017 1

Joe and Alun at the Don Whitley Scientific exhibition stand

Visitors to the Don Whitley Scientific got up close with two key DWS products. Firstly, the Whitley Jar Gassing System in which users can create perfect conditions for growing anaerobes in jars in just 2 minutes, a popular product which has been manufactured and sold by Don Whitley Scientific for decades. The Whitley A35 Anaerobic Workstation shares a similar concept to the WJGS in creating a reliable, anaerobic environment. The A35 provides the ability to manipulate samples in a sustainable environment where parameters can be altered to create the required conditions, unique features such as the Instant Access Porthole system make working in the chamber simple and straight forward.

MEDLAB is always a popular event and one that Don Whitley Scientific’s export team ensure to attend every year to promote the best Anaerobic Workstations on the market.

20170124_150718 cropped

Don Whitley Visits The Francis Crick Institute

Dr Don Whitley, chairman and founder of DWS, recently visited The Francis Crick Institute in London to see the recently installed Whitley H45 Hypoxystation at the site. 

The Crick has moved into a brand new state-of-the-art building in the centre of London. Situated next to Kings Cross and St Pancras stations, The Crick brings together 1500 scientists and staff working collaboratively in the biggest biomedical research facility under one roof in Europe. The work at The Crick covers many disciplines and applications in biomedical research, all with the aim of improving understanding of human health and disease.

 

Don Whitley established Don Whitley Scientific in 1976 and today Don Whitley Scientific Limited is a leading international supplier of innovative equipment and services to the microbiology and tissue culture industries. Recently DWS installed a H45 Hypoxystation into the institute, and Don Whitley went to visit the new customer with a member of the sales team.

20170124_145656 cropped

Don Whitley (far right) with one of the groups that will be using the Whitley H45 Hypoxystation

The Whitley H45 Hypoxystation has sufficient space to accommodate a variety of equipment whilst still providing generous working and incubation areas. Whitley Hypoxystations can be equipped with a range of unique options and features, including CO2 monitoring and automatic dehumidification fitted as standard, features that will make working with the H45 easy and efficient for the team at The Crick.

With his name featured on products in hundreds of clinical and research laboratories worldwide, it can be said that the staff at The Crick were excited to meet Don Whitley himself. The excitement was shared by Don, who enjoyed looking around one of the most exciting centres for biomedical research in the UK and taking a few pictures along the way.

 

20170124_152554

Don takes a photo looking out over the atrium of The Francis Crick Institute

 

Dr John Heap, Imperial College London

Realising the potential for synthetic biology

At Don Whitley Scientific we love to hear about the different applications and scientific disciplines in which our workstations are used. We recently came across a video of a presentation at the World Economic Forum in 2015. The clip is entitled: “Hacking exotic organisms and putting them to work“. Dr John Heap, who is an academic scientist and research group leader at Imperial College London, talks about harnessing diverse organisms including anaerobic bacteria, and realising the potential of synthetic biology for a variety of applications.

You will also see a very quick shot of Dr Heap using his Whitley Workstation!

For more information about Dr Heap and his work, here’s a link to the Heap Lab website.